Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

FDA Approval

Glycophos

CompanyFresenius Kabi USA, LLC (DUNS: 608775388)

Effective Date

December 7, 2022

Labeling Type

Human Prescription Drug Label

Active Ingredients

Sodium glycerophosphate(216 mg in 1 mL)

Manufacturing Establishments (1)

Fresenius Kabi Norge AS

Labeler

Fresenius Kabi USA, LLC

DUNS Number

731170932

Products (1)

Glycophos

NDC Product Code

63323-241

Route of Administration

INTRAVENOUS

Effective Date

January 16, 2019

Ingredients

Sodium glycerophosphateActive

Code: YP1H63LJ2KClass: ACTIRQuantity: 216 mg in 1 mL

HYDROCHLORIC ACIDInactive

Code: QTT17582CBClass: IACT

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy